ISDA

Entry Detail

PDB ID:

5TX5

Keywords:

transferase/transferase inhibitor

Title:

Rip1 Kinase ( flag 1-294, C34A, C127A, C233A, C240A) with GSK772

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

unidentified baculovirus

PDB Version:

Deposition Date:

2016-11-15

Release Date:

2017-07-05

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.56 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Receptor-interacting serine/threonine-protein kinase 1
Chain IDs:A, B
Chain Length:303
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q13546 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

7MJ

Primary Citation

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

Harris, P.A, Berger, S.B, Jeong, J.U, Nagilla, R, Bandyopadhyay, D, Campobasso, N, Capriotti, C.A, Cox, J.A, Dare, L, Dong, X, Eidam, P.M, Finger, J.N, Hoffman, S.J, Kang, J, Kasparcova, V, King, B.W, Lehr, R, Lan, Y, Leister, L.K, Lich, J.D, MacDonald, T.T, Miller, N.A, Ouellette, M.T, Pao, C.S, Rahman, A, Reilly, M.A, Rendina, A.R, Rivera, E.J, Schaeffer, M.C, Sehon, C.A, Singhaus, R.R, Sun, H.H, Swift, B.A, Totoritis, R.D, Vossenkamper, A, Ward, P, Wisnoski, D.D, Zhang, D, Marquis, R.W, Gough, P.J, Bertin, J.Show

J. Med. Chem. 60 1247 1261 (2017)

PMID: 28151659 DOI: 10.1021/acs.jmedchem.6b01751

Abstact

RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described. Herein, we report our lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clinical candidate GSK2982772 (compound 5), currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Compound 5 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous production of cytokines from human ulcerative colitis explants. The highly favorable physicochemical and ADMET properties of 5, combined with high potency, led to a predicted low oral dose in humans.

Legend

Protein

Chemical

Disease

Primary Citation of related structures